APA (7th ed.) Citation

Moreau, P., Dimopoulos, M., Mikhael, J., Yong, K., Capra, M., Facon, T., . . . Macé, S. (2021). Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): A multicentre, open-label, randomised phase 3 trial. Lancet, 397(10292), 2361. https://doi.org/10.1016/S0140-6736(21)00592-4

Chicago Style (17th ed.) Citation

Moreau, Philippe, et al. "Isatuximab, Carfilzomib, and Dexamethasone in Relapsed Multiple Myeloma (IKEMA): A Multicentre, Open-label, Randomised Phase 3 Trial." Lancet 397, no. 10292 (2021): 2361. https://doi.org/10.1016/S0140-6736(21)00592-4.

MLA (9th ed.) Citation

Moreau, Philippe, et al. "Isatuximab, Carfilzomib, and Dexamethasone in Relapsed Multiple Myeloma (IKEMA): A Multicentre, Open-label, Randomised Phase 3 Trial." Lancet, vol. 397, no. 10292, 2021, p. 2361, https://doi.org/10.1016/S0140-6736(21)00592-4.